Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Gynecologic 1

Conditions

Myelodysplastic Syndromes 5Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Squamous Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Leukemia 1Esophageal Squamous Cell Carcinoma 1Epidermolysis Bullosa Dystrophica 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Neoplasms × ON 01910 × Clear all
NCT00856791 2017-07-21

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Traws Pharma, Inc.

Phase 2 Completed
1 enrolled 5 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT01165905 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT01538537 2017-06-23

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT01538563 2017-06-23

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
42 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡